 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- || CD388 / Cidara Therap, J&J
Trial completion date, Trial primary completion date: NAVIGATE: Study of CD388 for the Prevention of Influenza in Subjects Not at Risk for Influenza Complications (clinicaltrials.gov) - Oct 20, 2024
P2, N=5000, Recruiting, Sponsor: Cidara Therapeutics Inc.
Trial completion date: May 2025 --> Sep 2025 | Trial primary completion date: May 2025 --> Sep 2025
- ||||| CD388 / Cidara Therap, J&J
New P2 trial: NAVIGATE: Study of CD388 for the Prevention of Influenza in Subjects Not at Risk for Influenza Complications (clinicaltrials.gov) - Sep 23, 2024
P2, N=5000, Recruiting, Sponsor: Cidara Therapeutics Inc.
- | CD388 / Cidara Therap, J&J
Phase classification: The Effectiveness of CD388 to Prevent Flu in an Influenza Challenge Model in Healthy Adults (clinicaltrials.gov) - Sep 4, 2024
P2, N=59, Completed, Sponsor: Cidara Therapeutics Inc.
Trial completion date: May 2025 --> Sep 2025 | Trial primary completion date: May 2025 --> Sep 2025 Phase classification: P2a --> P2
- CD388 / Cidara Therap, J&J
Single-Dose and Repeat Single-Dose Ascending Dose Study Evaluating Safety, Tolerability, and Pharmacokinetics of Subcutaneous and Intramuscular CD388, a Novel Long-acting Drug-Fc Conjugate for Universal Prevention of Seasonal and Pandemic Influenza (Halls JK) - Sep 4, 2024 - Abstract #IDWeek2024IDWEEK_2616;
- CD388 / Cidara Therap, J&J
CD388, a Novel Drug-Fc Conjugate (DFC), Demonstrates Prophylactic Activity in an Influenza Human Challenge Model (408 A) - Sep 4, 2024 - Abstract #IDWeek2024IDWEEK_961;
- CD388 / Cidara Therap, J&J
Single-Dose and Repeat Single-Dose Ascending Dose Study Evaluating Safety, Tolerability, and Pharmacokinetics of Subcutaneous and Intramuscular CD388, a Novel Long-acting Drug-Fc Conjugate for Universal Prevention of Seasonal and Pandemic Influenza (Halls JK - Arena 1) - Sep 4, 2024 - Abstract #IDWeek2024IDWEEK_852;
- ||| CD388 / Cidara Therap, J&J
Trial completion: Study of CD388 Intramuscular or Subcutaneous Administration in Healthy Subjects (clinicaltrials.gov) - Nov 13, 2023
P1, N=78, Completed, Sponsor: Cidara Therapeutics Inc.
Phase classification: P2a --> P2 Active, not recruiting --> Completed
- CD388 / Cidara Therap, J&J
Single Ascending Dose Safety, Tolerability, and Pharmacokinetics of Subcutaneous and Intramuscular CD388, a Novel Long-acting Drug-Fc Conjugate for Universal Prevention of Seasonal and Pandemic Influenza (Hall B + C) - Sep 6, 2023 - Abstract #IDWeek2023IDWeek_3022;
- CD388 / Cidara Therap, J&J
Efficacy of CD388, a Novel Drug Fc-Conjugate (DFC), is Driven by the Small Molecule Neuraminidase Inhibitor (NAI) (Hall B + C) - Sep 6, 2023 - Abstract #IDWeek2023IDWeek_2295;
- CD388 / Cidara Therap, J&J
In Vivo Efficacy of CD388, a Novel Drug Fc-Conjugate (DFC), Against Seasonal Subtypes of Influenza in Prophylaxis in Immune Competent Mice, and in a Severe Immunodeficient (SCID) Mouse Model (102 AB) - Sep 6, 2023 - Abstract #IDWeek2023IDWeek_1840;
- || CD388 / Cidara Therap, J&J
Trial completion: Study of CD388 Subcutaneous Administration in Healthy Japanese Subjects (clinicaltrials.gov) - Aug 1, 2023
P1, N=28, Completed, Sponsor: Cidara Therapeutics Inc.
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||| CD388 / Cidara Therap, J&J
Trial completion, Enrollment change: The Effectiveness of CD388 to Prevent Flu in an Influenza Challenge Model in Healthy Adults (clinicaltrials.gov) - Aug 1, 2023
P2a, N=59, Completed, Sponsor: Cidara Therapeutics Inc.
Active, not recruiting --> Completed Active, not recruiting --> Completed | N=168 --> 59
- || CD388 / Cidara Therap, J&J
Enrollment closed: Study of CD388 Subcutaneous Administration in Healthy Japanese Subjects (clinicaltrials.gov) - May 6, 2023
P1, N=27, Active, not recruiting, Sponsor: Cidara Therapeutics Inc.
Active, not recruiting --> Completed | N=168 --> 59 Recruiting --> Active, not recruiting
- || CD388 / Cidara Therap, J&J
Enrollment closed: Study of CD388 Intramuscular or Subcutaneous Administration in Healthy Subjects (clinicaltrials.gov) - May 3, 2023
P1, N=77, Active, not recruiting, Sponsor: Cidara Therapeutics Inc.
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- || CD388 / Cidara Therap, J&J
Enrollment closed, Trial completion date, Trial primary completion date: The Effectiveness of CD388 to Prevent Flu in an Influenza Challenge Model in Healthy Adults (clinicaltrials.gov) - Apr 4, 2023
P2a, N=168, Active, not recruiting, Sponsor: Cidara Therapeutics Inc.
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | Trial completion date: Oct 2023 --> Jul 2023 | Trial primary completion date: Oct 2023 --> Jul 2023
- || CD388 / Cidara Therap, J&J
Trial completion date, Trial primary completion date: Study of CD388 Intramuscular or Subcutaneous Administration in Healthy Subjects (clinicaltrials.gov) - Mar 20, 2023
P1, N=77, Recruiting, Sponsor: Cidara Therapeutics Inc.
Recruiting --> Active, not recruiting | Trial completion date: Oct 2023 --> Jul 2023 | Trial primary completion date: Oct 2023 --> Jul 2023 Trial completion date: Mar 2023 --> Nov 2023 | Trial primary completion date: Mar 2023 --> Nov 2023
- ||| CD388 / Cidara Therap, J&J
Enrollment open: The Effectiveness of CD388 to Prevent Flu in an Influenza Challenge Model in Healthy Adults (clinicaltrials.gov) - Feb 2, 2023
P2a, N=168, Recruiting, Sponsor: Cidara Therapeutics Inc.
Trial completion date: Mar 2023 --> Nov 2023 | Trial primary completion date: Mar 2023 --> Nov 2023 Not yet recruiting --> Recruiting
- || CD388 / Cidara Therap, J&J
Enrollment change, Trial completion date, Trial primary completion date: Study of CD388 Subcutaneous Administration in Healthy Japanese Subjects (clinicaltrials.gov) - Jan 20, 2023
P1, N=27, Recruiting, Sponsor: Cidara Therapeutics Inc.
Not yet recruiting --> Recruiting N=18 --> 27 | Trial completion date: Mar 2023 --> Jun 2023 | Trial primary completion date: Mar 2023 --> Jun 2023
- || CD388 / Cidara Therap, J&J
New P1 trial: Study of CD388 Subcutaneous Administration in Healthy Japanese Subjects (clinicaltrials.gov) - Nov 17, 2022
P1, N=18, Recruiting, Sponsor: Cidara Therapeutics Inc.
- |||| CD388 / Cidara Therap, J&J
New P2a trial: The Effectiveness of CD388 to Prevent Flu in an Influenza Challenge Model in Healthy Adults (clinicaltrials.gov) - Aug 31, 2022
P2a, N=168, Not yet recruiting, Sponsor: Cidara Therapeutics Inc.
- ||| CD388 / Cidara Therap, J&J
New P1 trial: Study of CD388 Intramuscular or Subcutaneous Administration in Healthy Subjects (clinicaltrials.gov) - Mar 16, 2022
P1, N=66, Recruiting, Sponsor: Cidara Therapeutics Inc.